Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy

The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks

GSK seeks European nod for promising Hepatitis B therapy

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

HRV Pharma and Shodhana Laboratories forge CDMO Alliance

The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments